Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2020 Nov 19;7(11):71.
doi: 10.3390/medicines7110071.

Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2

Kyohei Araki  1 , Yasuyoshi Miyata  1 , Kojiro Ohba  1 , Yuichiro Nakamura  1 , Tomohiro Matsuo  1 , Yasushi Mochizuki  1 , Hideki Sakai  1
Affiliations
Published Erratum

Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2

Kyohei Araki et al. Medicines (Basel). .

Abstract

We, the authors, wish to make the following correction to our published paper [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Erratum for

Similar articles

See all similar articles

References

    1. Araki K., Miyata Y., Ohba K., Nakamura Y., Matsuo T., Mochizuki Y., Sakai H. Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines. 2019;6:2. doi: 10.3390/medicines6010002. - DOI - PMC - PubMed

Publication types

LinkOut - more resources